Navigation Links
A Breakthrough in the Study of Hepatitis C

Researchers have devised a novel viral culture system, which makes way for a better study of Hepatitis C virus. This system enables the replication of virus// (isolated from patient) in non-transformed hepatocytes. Systems in vogue involve culture of permissive viral strains in transformed cell lines.

The study report by Lázaro et al, ‘Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes,’ appears in the February issue of The American Journal of Pathology.

Hepatitis C virus (HCV) infection affects approximately 170,000,000 people worldwide. HCV liver disease, which may induce liver inflammation, cirrhosis, and/or hepatocellular carcinoma, represents the foremost reason for liver transplantation in much of the U.S.

Study of HCV replication within liver cells, or hepatocytes, has been hampered by a lack of adequate virus culture systems. Some systems allow the virus to infect cells but do not permit prolonged replication and production of virus, while other systems rely on derivatives of permissive virus isolates for efficient replication in transformed (mutated) cell lines. Still lacking has been a system to sustain replication of novel virus isolates from patients using nontransformed hepatocytes.

Nelson Fausto of the University of Washington School of Medicine has crossed this hurdle using a human fetal hepatocyte culture system that was previously developed in his lab. Using this system, his group has demonstrated sustained replication and production of virus particles for at least 2 months, with these virus particles able to infect new cells.

In their first experiments, Fausto and colleagues transfected hepatocyte cultures with HCV genomic RNA and found replication of HCV RNA genomes and production of core protein (for virus particle formation). Release of infectious virus particles was confirmed, as media from these cells were able to infect naive hepatocytes. Finally, virus particles were examined by electron microscopy and shown to possess the expected size and shape of HCV virus particles.

Once the system was established, the group examined whether sera from patients carrying HCV could infect the human fetal hepatocytes. When sera from patients infected with different HCV strains were added to the hepatocyte culture system, viral replication occurred and new virus particles were produced.

In both transfection and infection models, virus particles were released in a cyclical manner, with bursts of virus produced every 10-14 days. This is similar to what has been reported during clinical HCV infection, possibly due to the host's natural defenses. Interestingly, cultured hepatocytes responded to viral replication by displaying signs of distress and cell death and by expressing interferon-beta, a cellular antiviral, in an effort to control the infection.

This culture system provides a breakthrough in studying HCV replication in nontransformed hepatocytes, the natural target of the virus. By allowing infection by patient serum containing a wide array of virus strains, this system may allow better understanding of the differences between different strains, further improving treatment strategies.

Source-Eurekalert
RI
'"/>




Related medicine news :

1. Sperm washing helps couples – Breakthrough in focu
2. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
3. Breakthrough in eye treatment
4. Genetic Breakthrough in Common Eye Problem
5. Breakthrough in cancer therapy
6. Breakthrough in Type II Diabetes
7. Breakthrough In Stem Cell Work
8. A Likely Breakthrough For Prostate Cancer Patients
9. New DNA Breakthrough Can Change Future Of Medicine
10. Breakthrough In New Vaccine For Malaria
11. Medical Breakthrough - Kidney Transplant Recipient Survives Without Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2016)... SC (PRWEB) , ... February 08, 2016 , ... Steve ... areas with a vital new community enrichment program, has teamed up with Citizens Opposed ... and children suffering from intimate abuse. To support all those victimized by the fear ...
(Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should ... Bentonite Clay” the health benefits of integrating clay into a daily diet are numerous, ... former motivational speaker, Perry A~ has since dedicated her life to learning about the ...
(Date:2/8/2016)... ... February 08, 2016 , ... The ... important news! AHCC and the Home Health and Hospice ICD-10 Transition Workgroup are ... official ICD coding guidance and clarifications, to address concerns over the use of ...
(Date:2/8/2016)... ... 2016 , ... According to research by the National Association ... to be certified or obtain continuing education. To increase patient awareness of the ... Mouth?” campaign to inform dentists and patients about the possible lack of skills ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This ... an estimated 5000 perioperative nurses in attendance to study the latest evidence-based ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... ANN ARBOR, Mich. , Feb. 8, 2016 /PRNewswire-USNewswire/ ... Ann Arbor announced today that, as part ... will become one of the first hospitals in the ... Karin Muraszko , M.D., U-M,s chair of ... U-M,s chair of neurosurgery. --> The ...
(Date:2/8/2016)... 2016 Velano Vascular, a medical technology company ... and their practitioners, announced today that the company has ... use the proceeds from this financing, an extension of ... 2015, to support the development and commercialization of the ... Philadelphia , and a ...
(Date:2/8/2016)... 2016  HemaFlo Therapeutics, Inc. announced today that the United ... Number 9,119,880 covering the use of NephroFlow to treat acute ... HemaFlo,s founder, said, "We are pleased to secure our rights ... Peterson , PhD, HemaFlo,s founder, said, "We are pleased to ... --> Dale Peterson , PhD, HemaFlo,s founder, said, ...
Breaking Medicine Technology: